How do you approach patients with AL amyloidosis with t(11;14) who have not achieved a hematologic complete response to induction therapy with 6 cycles of Dara-CyBorD?

Achieving an early hem deep response (at least VGPR or better) is crucial for organ response and has demonstrated OS benefit.

I would favor changing treatment even by cycle 4 if the hematologic response is <PR. Early switch in such situations led to improved EFS and better chances for an organ respon...

Excellent question, and always a frustrating scenario because of how excitedly we discuss the rise of daratumumab with our newly diagnosed patients when they're diagnosed and feeling terrible.

I assume the patient here doesn't have any myeloma-defining events, which is a story for another day (and pr...